Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Knightscope
Sponsored
content by Knightscope
MA
MarketJar
Community Contributor
The Next Phase of Defense AI: A Robotic Response to America’s Security Gaps
Autonomous systems are no longer just a futuristic vision — they’re fast becoming an essential layer of national security. As AI reshapes everything from finance to warfare, physical security remains one of the most under-addressed frontiers.
View narrative
US$12.00
FV
50.7% undervalued
intrinsic discount
22.00%
Revenue growth p.a.
Set Fair Value
10
users have liked this narrative
1
users have commented on this narrative
44
users have followed this narrative
8 days ago
author updated this narrative
Figma
TI
TickerTickle
Community Contributor
Figma (FIG): The S&P 500’s Design Standard Turning Into an All-in-One Platform
Watching Figma Grow Up I’ve been using Figma almost every single day for the past five years. As a product designer, it’s been my main tool for designing interfaces, testing and prototyping ideas, and also for working together with teams in different countries and time zones.
View narrative
US$65.70
FV
8.5% overvalued
intrinsic discount
30.00%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
1
users have commented on this narrative
19
users have followed this narrative
Updated
narrative
Sleep Cycle
MA
Mandelman
Community Contributor
Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model
Update Q1 2025 (updated 250510) The latest user‐growth data suggest headwinds for top-line revenue, but management’s active repricing initiatives should help offset this. By combining modest user gains with targeted price increases, the company can still drive overall revenue growth.
View narrative
SEK 38.04
FV
18.4% undervalued
intrinsic discount
3.15%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
2
users have commented on this narrative
37
users have followed this narrative
Updated
narrative
JB Hi-Fi
RO
Robbo
Community Contributor
Has JB Hi-Fi Lost Its Point of Difference?
I may be showing my age here, but I feel that a decade or so ago, shopping at JB Hi-Fi was a different experience. There seemed to be a deliberate policy of employing sales staff from alternative subcultures, which gave the stores a unique, edgy vibe.
View narrative
AU$76.00
FV
51.6% overvalued
intrinsic discount
-0.45%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
1
users have commented on this narrative
11
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
KCB Group
AN
AnalystLowTarget
Consensus Narrative from 4 Analysts
Rising Geopolitical And Fintech Risks Will Undermine Future Prospects
Key Takeaways Geopolitical instability, currency volatility, and rising compliance demands threaten KCB's asset quality, revenue growth, and cost efficiency across its regional operations. Intensifying fintech competition and slow digital innovation risk eroding KCB's market share, fee income, and long-term earnings potential.
View narrative
KSh44.00
FV
22.7% overvalued
intrinsic discount
12.25%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
0
users have followed this narrative
New
narrative
AXT
AN
AnalystHighTarget
Consensus Narrative from 5 Analysts
AI And 5G Will Ignite Compound Semiconductor Revolution
Key Takeaways Demand for advanced substrates in AI, cloud, electrification, and wireless markets positions AXT for significant revenue and margin expansion over time. Vertical integration and a potential Tongmei IPO could drive financial resilience, hidden value realization, and improved competitive positioning.
View narrative
US$5.00
FV
41.6% undervalued
intrinsic discount
21.11%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
ARS Pharmaceuticals
AN
AnalystHighTarget
Consensus Narrative from 5 Analysts
Needle-Free Allergy Therapies Will Capture Untapped Global Markets
Key Takeaways Neffy's needle-free delivery is expanding the allergy treatment market, attracting previously untreated patients and driving greater-than-expected revenue and prescription growth. Enhanced insurance coverage, multi-pack purchasing, and strategic positioning are accelerating recurring sales, expanding margins, and making ARS attractive for global partnerships or acquisition.
View narrative
US$40.00
FV
67.9% undervalued
intrinsic discount
65.99%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
GT
Goodyear Tire & Rubber
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Persisting Trade Threats Will Depress Margins While Niche Launches Emerge
Key Takeaways Persistent pricing pressure from low-cost imports and volatile trade conditions threatens sustainable improvements to margins despite new product focus and possible tariff support. High debt levels, weak demand, and industry uncertainty constrain earnings growth and limit flexibility for investment in future innovations and premium offerings.
View narrative
US$9.00
FV
5.3% undervalued
intrinsic discount
-0.86%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Gold Royalty
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Increased Gold Risk And Costly Royalties Will Undermine Outlook
Key Takeaways Weakening gold demand and increased digital asset adoption present structural threats to long-term royalty income and growth potential. Environmental regulations and sector overcapacity risk shrinking the project pipeline and compressing profit margins over time.
View narrative
US$3.25
FV
0.9% overvalued
intrinsic discount
53.94%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Anglo American
AN
AnalystHighTarget
Consensus Narrative from 16 Analysts
Electrification And Urbanization Will Ignite Automated Copper And Iron Demand
Key Takeaways Accelerated operational improvements and project execution could enable a shift to a high-margin, copper and iron ore-focused business model faster than anticipated. Strategic assets and expansion projects position Anglo for outsized growth and margin expansion, supported by innovation and strong ESG credentials amid tightening mineral markets.
View narrative
UK£27.69
FV
18.2% undervalued
intrinsic discount
-2.90%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Apellis Pharmaceuticals
AN
AnalystHighTarget
Consensus Narrative from 18 Analysts
Expanded Labels And Complement Pipeline Will Capture Global Aging Markets
Key Takeaways EMPAVELI and SYFOVRE are positioned to capture dominant market shares and drive sustained revenue growth through broad adoption and durable clinical efficacy. Advances in pipeline therapies and operational discipline strengthen both profit margins and long-term earnings leverage, setting Apellis apart from industry peers.
View narrative
US$60.00
FV
53.3% undervalued
intrinsic discount
23.99%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Monde Nissin
AN
AnalystHighTarget
Consensus Narrative from 11 Analysts
Urbanization And Digitalization Will Drive Quorn Market Leadership
Key Takeaways Rapid gross margin expansion, supply chain overhaul, and SKU rationalization are likely to drive earnings and profitability beyond current expectations. Strong growth in Meat Alternatives and dominance in core segments, supported by digital distribution and innovation, position the company for sustained high-margin revenue growth.
View narrative
₱13.28
FV
45.5% undervalued
intrinsic discount
6.71%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Medco Energi Internasional
AN
AnalystLowTarget
Consensus Narrative from 12 Analysts
Rising Decarbonization And Debt Will Shrink Margins But Enable Resilience
Key Takeaways Exposure to energy transition risks and renewables growth threatens Medco's long-term fossil fuel demand, reserve stability, and future earnings sustainability. High leverage, refinancing dependence, and market volatility may increase funding costs and limit growth opportunities as ESG expectations rise.
View narrative
Rp1.31k
FV
8.5% undervalued
intrinsic discount
-5.92%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
New
narrative
Value any company in seconds
Popular companies